Compounds > irinotecan
Page last updated: 2024-08-24

irinotecan and Experimental Neoplasms

irinotecan has been researched along with Experimental Neoplasms in 86 studies

Research

Studies (86)

TimeframeStudies, this research(%)All Research%
pre-19903 (3.49)18.7374
1990's15 (17.44)18.2507
2000's25 (29.07)29.6817
2010's38 (44.19)24.3611
2020's5 (5.81)2.80

Authors

AuthorsStudies
Baguley, BC; Deady, LW; Denny, WA; Rodemann, T; Zhuang, L1
Chang, LC; Goto, M; Hung, HY; Kuo, DH; Kuo, SC; Lee, KH; Liu, YQ; Morris-Natschke, SL; Nan, X; Pan, SL; Qian, K; Teng, CM; Wang, CY; Wang, MJ; Wu, TS; Wu, YC; Yang, JS; Yang, L; Yang, XM; Zhao, XB; Zhao, YL1
Chen, Y; Lu, W; Ma, L; Wang, L; Xie, S1
Jiang, Z; Li, ZR; Sha, MQ; Shen, JJ; Wang, Z; Wu, LT; Xue, ST; Yi, H; Zhan, YC1
Barlaam, B; Cadogan, E; Degorce, SL; Dishington, A; Ducray, R; Glossop, SC; Hassall, LA; Lach, F; Lau, A; McGuire, TM; Nowak, T; Ouvry, G; Pike, KG; Thomason, AG1
Artali, R; Bianchino, E; Cardile, F; Cincinelli, R; Colelli, F; Dallavalle, S; Guglielmi, M; Musso, L; Pisano, C1
Cheng, L; Du, Y; He, W; Li, X; Wang, J; Wang, T1
Brenner, AJ; Chiou, J; Gruslova, A; Pandey, R; Tiziani, S1
Erickson, SW; Gorlick, R; Guo, Y; Houghton, PJ; Kolb, EA; Kurmasheva, RT; Maris, JM; Mosse, YP; Smith, MA; Teicher, BA1
Chen, W; Ding, N; Lin, Z; Ling, S; Wang, L; Xie, S; Xu, L; Xu, S; Xu, X; Xue, M; Ye, Q; Zhang, Z; Zheng, S1
Chang, CH; Donahue, T; Jiang, J; Liao, YP; Lin, J; Lin, P; Liu, X; Meng, H; Nel, AE; Perrett, I; Wainberg, Z; Wu, N1
Doi, H; Inui, T; Kataoka, Y; Kida, T; Nakatsuji, M; Nishino, K; Sakamoto, S; Shimizu, S; Tamura, Y; Teraoka, Y1
Chen, X; Gu, D; Huang, Q; Liu, X; Shen, Y; Si, J; Sui, M; Yang, H; Zhang, Q1
Bai, S; Gao, YE; Hou, M; Kang, Y; Ma, X; Shi, X; Xiao, B; Xu, Z; Xue, P; Zhang, T1
Choi, HG; Gautam, M; Jin, SG; Kim, JO; Ku, SK; Nguyen, HT; Oh, KT; Ou, W; Soe, ZC; Thapa, RK; Yong, CS1
Abd El-Aty, AM; Cetin, M; Galateanu, B; Gundogdu, B; Hacimuftuoglu, A; Jeong, JH; Jung, TW; Mezhuev, Y; Mohammadzadeh, M; Nalci, KA; Okkay, U; Stivaktakis, P; Taghizadehghalehjoughi, A; Taspinar, M; Taspinar, N; Tsatsakis, A; Ugur, AB; Uyanik, A1
Chiang, CS; Chiang, WH; Chiu, HC; Hung, CK; Liu, TI; Lo, CL; Tsai, YC; Yang, YC1
Butler, R; Stringer, A; Sultani, M; Thorpe, D; Vanhoecke, B1
Choi, S; Kim, E; Koo, H; Son, J; Yi, G; Yoo, J1
Chen, Y; Cheng, G; Lee, RJ; Wang, J; Wang, K; Yao, J; Yu, B; Zhang, C; Zhang, X; Zhang, Y1
Del Bene, F; Germani, M; Magni, P; Terranova, N1
Blackwood, E; Del Nagro, C; Evangelista, M; Jackson, PK; Kowanetz, K; Malek, S; O'Brien, T; Ramiscal, J; Xiao, Y1
Bloomfield, A; Dorton, R; Guan, J; Leamon, CP; Nelson, M; Reddy, JA; Vetzel, M1
Bhuniya, S; Hong, KS; Kim, EJ; Kim, JS; Lee, H; Maiti, S; Sessler, JL1
Chen, Q; Chen, S; Huang, C; Li, J; Liao, J; Liu, F; Su, G; Tang, W; Ye, Y1
Chen, L; Ci, T; Ding, J; Yu, L1
Eldon, MA; Hoch, U; Johnson, RK; Staschen, CM1
Bhuniya, S; Cheong, C; Hong, KS; Kim, EJ; Kim, HM; Kim, JS; Lee, H; Maiti, S1
Bouard, C; Boumendjel, A; Di Pietro, A; Gauthier, C; Gervot, H; Guitton, J; Honorat, M; Lecerf-Schmidt, F; Payen, L; Peres, B; Puisieux, A; Rioufol, C; Terreux, R1
Choi, HG; Choi, JY; Kim, JH; Kim, JO; Ku, SK; Ramasamy, T; Ruttala, HB; Tran, TH; Yong, CS1
Matsui, H; Nagasaki, Y; Vong, LB; Yoshitomi, T1
Cano, F; Carcaboso, AM; Manzanares, A; Monterrubio, C; Mora, J; Pascual-Pasto, G; Schaiquevich, P; Sosnik, A; Tornero, JA; Vila-Ubach, M1
Bhuniya, S; Han, J; Hong, KS; Kim, EJ; Kim, HM; Kim, JS; Kumar, R; Lee, H; Shin, WS1
Choi, HG; Choi, JY; Din, FU; Kim, DS; Kim, DW; Kim, JO; Ku, SK; Mustapha, O; Oh, KT; Oh, YK; Thapa, RK; Yong, CS; Youn, YS1
Adam, MJ; Anantha, M; Baker, JH; Bally, MB; Co, SJ; Dragowska, WH; Kozlowski, P; Kyle, AH; Lam, J; Minchinton, AI; Ng, SS; Oliver, T; Ramsay, E; Ruth, TJ; Sy, J; Yapp, DT; Yung, A1
Askenasy, N; Fabian, I; Halperin, D; Reuveni, D; Shalit, I; Tsarfaty, G1
Becherini, P; Cilli, M; Emionite, L; Greenberger, LM; Horak, ID; Loi, M; Pastorino, F; Ponzoni, M; Ribatti, D; Sapra, P1
Manabe, S; Matsumura, Y; Yasunaga, M1
Azrak, RG; Bhattacharya, A; Cao, S; Durrani, FA; Rustum, YM; Toth, K1
Furuta, T; Hashimoto, S; Kodaira, H; Kurita, A; Matsuzaki, T; Nohara, G; Sawada, S; Takagi, A; Ueno, S1
Chen, J; Gu, Q; He, C; Huang, M; Xing, JZ1
Granot, T; Meruelo, D1
Ding, LY; Guo, M; Liu, YQ; Lu, Y; Ron, WT; Song, FF; Wang, Y; Yu, SQ1
Cha, H; Cho, WJ; Lee, HY; Lee, JC; Lee, SJ; Lee, YH; Min, YJ; Moon, CH; Park, HJ; Park, JW; Seo, J; Song, HT1
Kutner, A; Maciejewska, M; Milczarek, M; Psurski, M; Rosinska, S; Wietrzyk, J1
Coudray, AM; De Gramont, A; Faivre, S; Gespach, C; Louvet, C; Raymond, E; Tournigand, C1
Fang, HB; Houghton, PJ; Tan, M; Tian, GL3
Ahmad, I; Ali, S; Ma, L; Parmar, M; Ugwu, S; Xuan, T; Zhang, JA1
Blackman, RK; Bulawa, CE; Charlton, P; Connolly, K; Fleming, JA; McClendon, AK; Osheroff, N; Reimer, C; Rudolph-Owen, LA; Sappal, DS; Thoroddsen, V1
Sasako, M; Ushijima, T1
Chen, LB; Dai, M; Owen, DA; Tai, IT1
Mai, M; Takahashi, Y; Yasumoto, K1
Bucana, CD; Carter, KB; Jasser, SA; Kim, S; Myers, JN; Wang, Z; Yazici, YD1
Boltze, C; Fahlke, J; Hribaschek, A; Kuhn, R; Lippert, H; Meyer, F; Pross, M; Ridwelski, K1
Camuso, A; Castaneda, S; Fager, K; Flefleh, C; Inigo, I; Kan, D; Luo, FR; McGlinchey, K; Rose, WC; Wild, R1
Hata, K; Koyanagi, S; Kuramoto, Y; Ohdo, S; Shimeno, H; Soeda, S1
Belfiore, P; Croce, AC; Dal Bo, L; Farina, C; Misiano, P; Petrangolini, G; Pratesi, G; Supino, R; Tortoreto, M; Zunino, F1
Benedetti, V; Beretta, GL; Carminati, P; Dallavalle, S; De Cesare, M; Merlini, L; Penco, S; Pisano, C; Pratesi, G; Tinelli, S; Zunino, F1
Cao, S; Creaven, PJ; Durrani, FA; Iyer, RV; Javle, MM; Lawrence, DD; Noel, DC; Pendyala, L; Rustum, YM; Smith, PF1
Dubois, RN; Hatakeyama, N; Horikawa, Y; Jin, M; Komatsu, K; Matsuhashi, T; Odashima, M; Ohba, R; Otaka, M; Oyake, J; Wada, I; Watanabe, S1
Anantha, M; Bally, MB; Meijs, M; Ramsay, EC; Strutt, D; Waterhouse, D; Webb, MS; Zastre, J; Zonderhuis, J1
Baracos, VE; Dieleman, LA; Field, CJ; Murray, D; Sawyer, MB; Xue, H1
Arranz, V; Boukaissi, M; Chéné, AS; de Coupade, C; Dubois, V; Fruchart, JS; Kearsey, J; Meyer-Losic, F; Michel, M; Nicolazzi, C; Quinonero, J; Ravel, D; Ribes, F; Tranchant, I; Zoubaa, I1
Cheshire, PJ; Danks, MK; Friedman, HS; Hallman, JD; Houghton, JA; Houghton, PJ; Lutz, L1
Armand, JP1
André, S; Bissery, MC; Lavelle, F; Riou, JF; Roquet, F1
Bissery, MC; Chabot, GG; Lavelle, F; Vrignaud, P1
Fukuoka, M; Kudoh, S; Masuda, N1
Danks, MK; Houghton, JA; Houghton, PJ; Luo, X; Stewart, CF; Thompson, J; Zamboni, WC1
Bugat, R; Canal, P; Cussac, D; Guichard, S; Hennebelle, I1
Aoyagi, K; Aoyagi, Y; Asao, T; Okazaki, S; Sano, M; Utsugi, T; Wierzba, K; Yamada, Y1
Saijo, N1
Canal, P; Chabot, GG; Lokiec, F; Robert, J1
Baldwin, AS; Cusack, JC; Liu, R; Wang, CY1
Cheshire, PJ; Danks, MK; Houghton, PJ; Krull, EJ; Morton, CL; Naeve, CW; Pawlik, CA; Potter, PM; Richmond, LB1
Boushey, RP; Drucker, DJ; Yusta, B1
Agrawal, S; Ball, R; Chen, SF; Dexter, DL; Hollister, BA; Kandimalla, ER; Lombardi, G; Lucas, T; Yu, D1
Agrawal, S; Hang, J; Kandimalla, ER; Li, M; Shi, Z; Wang, H; Yu, D; Zhang, R1
Hirabayashi, N; Jinushi, K; Kim, R; Nishiyama, M; Okada, K; Toge, T1
Taguchi, T1
Furuta, T; Yokokura, T1
Matsushita, M; Matsuzaki, T; Saito, H; Tsuruo, T; Yokokura, T1
Baba, H; Kunimoto, T; Miyasaka, T; Mutai, M; Nitta, K; Sawada, S; Takeuchi, M; Tanaka, T; Uehara, N; Yokokura, T2

Reviews

6 review(s) available for irinotecan and Experimental Neoplasms

ArticleYear
Focus on gastric cancer.
    Cancer cell, 2004, Volume: 5, Issue:2

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Cadherins; Camptothecin; Carcinogens; Docetaxel; Fluorouracil; Gerbillinae; Herpesvirus 4, Human; Humans; Irinotecan; Lymphatic Metastasis; Mice; Mice, Transgenic; Models, Animal; Mutation; Neoplasm Staging; Neoplasms, Experimental; Rats; Stomach Neoplasms; Taxoids

2004
Preclinical evaluation of CPT-11 and its active metabolite SN-38.
    Seminars in oncology, 1996, Volume: 23, Issue:1 Suppl 3

    Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; DNA Damage; Drug Resistance; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms, Experimental; Topoisomerase I Inhibitors

1996
Irinotecan (CPT-11): pharmacology and clinical applications.
    Critical reviews in oncology/hematology, 1996, Volume: 24, Issue:1

    Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Humans; Irinotecan; Neoplasms; Neoplasms, Experimental

1996
New chemotherapeutic agents for the treatment of non-small cell lung cancer: the Japanese experience.
    Chest, 1998, Volume: 113, Issue:1 Suppl

    Topics: Alkaloids; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbazoles; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Glucosides; Humans; Irinotecan; Japan; Lung Neoplasms; Mitomycin; Mitomycins; Neoplasms, Experimental; Paclitaxel; Purine Nucleosides; Staurosporine; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine

1998
[Irinotecan pharmacokinetics].
    Bulletin du cancer, 1998, Volume: Spec No

    Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Biotransformation; Blood Proteins; Body Fluid Compartments; Camptothecin; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Half-Life; Humans; Inactivation, Metabolic; Irinotecan; Liver; Mice; Models, Biological; Neoplasm Proteins; Neoplasms; Neoplasms, Experimental; Prodrugs; Rats; Tissue Distribution; Topoisomerase I Inhibitors

1998
[DNA topoisomerase inhibitor as chemotherapeutic drug--clinical point of view].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1991, Volume: 18, Issue:10

    Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Dogs; Drug Evaluation; Female; Genital Neoplasms, Female; Humans; Irinotecan; Leukocyte Count; Lung Neoplasms; Mice; Neoplasms, Experimental; Topoisomerase I Inhibitors

1991

Trials

1 trial(s) available for irinotecan and Experimental Neoplasms

ArticleYear
Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Feb-01, Volume: 13, Issue:3

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Colorectal Neoplasms; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Fluorouracil; Glucuronates; Humans; Intestinal Mucosa; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Mucositis; Neoplasm Transplantation; Neoplasms, Experimental; Pyrazoles; Rats; Rats, Inbred F344; Sulfonamides

2007

Other Studies

79 other study(ies) available for irinotecan and Experimental Neoplasms

ArticleYear
Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridines.
    Journal of medicinal chemistry, 2003, Mar-13, Volume: 46, Issue:6

    Topics: Animals; Antineoplastic Agents; Cell Division; Drug Screening Assays, Antitumor; Humans; Mice; Naphthyridines; Neoplasm Transplantation; Neoplasms, Experimental; Structure-Activity Relationship; Transplantation, Heterologous; Tumor Cells, Cultured

2003
Design, synthesis, mechanisms of action, and toxicity of novel 20(s)-sulfonylamidine derivatives of camptothecin as potent antitumor agents.
    Journal of medicinal chemistry, 2014, Jul-24, Volume: 57, Issue:14

    Topics: Amidines; Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Female; HCT116 Cells; Humans; KB Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Conformation; Neoplasms, Experimental; Structure-Activity Relationship; Sulfonamides; Topoisomerase I Inhibitors

2014
Design, synthesis and biological evaluation of novel homocamptothecin analogues as potent antitumor agents.
    Bioorganic & medicinal chemistry, 2015, May-01, Volume: 23, Issue:9

    Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; HT29 Cells; Humans; Mice; Molecular Structure; Neoplasms, Experimental; Structure-Activity Relationship; Xenograft Model Antitumor Assays

2015
Design, synthesis and biological evaluation of novel benzimidazole-2-substituted phenyl or pyridine propyl ketene derivatives as antitumour agents.
    European journal of medicinal chemistry, 2016, May-23, Volume: 114

    Topics: Animals; Antineoplastic Agents; Benzimidazoles; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Ethylenes; HCT116 Cells; Hep G2 Cells; Humans; Ketones; MCF-7 Cells; Mice; Mice, Inbred BALB C; Molecular Structure; Neoplasms, Experimental; Structure-Activity Relationship

2016
Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase.
    Journal of medicinal chemistry, 2016, 07-14, Volume: 59, Issue:13

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Humans; Mice; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Protein Kinase Inhibitors; Quinolines; Structure-Activity Relationship; Xenograft Model Antitumor Assays

2016
Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
    European journal of medicinal chemistry, 2018, Jan-01, Volume: 143

    Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Proliferation; Cells, Cultured; Disulfides; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Mice; Mice, Nude; Models, Molecular; Molecular Structure; Neoplasms, Experimental; Structure-Activity Relationship; Topoisomerase I Inhibitors; Tyrosine

2018
Dimeric Artesunate-Phosphatidylcholine-Based Liposomes for Irinotecan Delivery as a Combination Therapy Approach.
    Molecular pharmaceutics, 2021, 10-04, Volume: 18, Issue:10

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Artesunate; Cell Line, Tumor; Drug Combinations; Drug Delivery Systems; Female; Irinotecan; Liposomes; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Phosphatidylcholines

2021
Stable Isotope Dilution LC-HRMS Assay To Determine Free SN-38, Total SN-38, and SN-38G in a Tumor Xenograft Model after Intravenous Administration of Antibody-Drug Conjugate (Sacituzumab Govitecan).
    Analytical chemistry, 2020, 01-07, Volume: 92, Issue:1

    Topics: Administration, Intravenous; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Chromatography, High Pressure Liquid; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Immunoconjugates; Indicator Dilution Techniques; Irinotecan; Mass Spectrometry; Mice; Mice, SCID; Molecular Structure; Neoplasms, Experimental

2020
Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report.
    Pediatric blood & cancer, 2020, Volume: 67, Issue:5

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Child; Female; Humans; Irinotecan; Kidney Neoplasms; Mice; Mice, SCID; Neoplasms, Experimental; Neuroblastoma; Pyrazoles; Pyrimidinones; Wilms Tumor; Xenograft Model Antitumor Assays

2020
"Sweet tooth"-oriented SN38 prodrug delivery nanoplatform for targeted gastric cancer therapy.
    Journal of materials chemistry. B, 2021, 03-28, Volume: 9, Issue:12

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Drug Delivery Systems; Drug Liberation; Drug Screening Assays, Antitumor; Humans; Irinotecan; Kinetics; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Nanoparticles; Neoplasms, Experimental; Prodrugs; Stomach Neoplasms; Tumor Cells, Cultured

2021
Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer.
    The Journal of clinical investigation, 2017, May-01, Volume: 127, Issue:5

    Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Pancreatic Ductal; Humans; Irinotecan; Mice; Nanoparticles; Neoplasm Metastasis; Neoplasms, Experimental; Oligopeptides; Silicon Dioxide; Transcytosis; Xenograft Model Antitumor Assays

2017
Solubility-Improved 10-O-Substituted SN-38 Derivatives with Antitumor Activity.
    ChemMedChem, 2017, 10-20, Volume: 12, Issue:20

    Topics: Animals; Antineoplastic Agents; Camptothecin; Humans; Irinotecan; Male; Mice; Molecular Structure; Neoplasms, Experimental; Prostatic Neoplasms; Structure-Activity Relationship

2017
Functionalized Nanoparticles Efficiently Enhancing the Targeted Delivery, Tumor Penetration, and Anticancer Activity of 7-Ethyl-10-Hydroxycamptothecin.
    Advanced healthcare materials, 2018, Volume: 7, Issue:7

    Topics: Animals; Cell Line, Tumor; Drug Delivery Systems; Humans; Irinotecan; Mice; Neoplasms, Experimental; Polyethylene Glycols; Prodrugs; Xenograft Model Antitumor Assays

2018
Irinotecan delivery by unimolecular micelles composed of reduction-responsive star-like polymeric prodrug with high drug loading for enhanced cancer therapy.
    Colloids and surfaces. B, Biointerfaces, 2018, Oct-01, Volume: 170

    Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Biocompatible Materials; Camptothecin; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Screening Assays, Antitumor; HeLa Cells; Humans; Injections, Intravenous; Irinotecan; MCF-7 Cells; Mice; Micelles; Molecular Structure; Neoplasms, Experimental; Oxidation-Reduction; Particle Size; Polymers; Prodrugs; Structure-Activity Relationship; Surface Properties

2018
Folate receptor-mediated celastrol and irinotecan combination delivery using liposomes for effective chemotherapy.
    Colloids and surfaces. B, Biointerfaces, 2018, Oct-01, Volume: 170

    Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Cycle; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Carriers; Drug Screening Assays, Antitumor; Folate Receptors, GPI-Anchored; Humans; Irinotecan; Liposomes; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Pentacyclic Triterpenes; Structure-Activity Relationship; Triterpenes; Tumor Cells, Cultured

2018
Effect of metformin/irinotecan-loaded poly-lactic-co-glycolic acid nanoparticles on glioblastoma: in vitro and in vivo studies.
    Nanomedicine (London, England), 2018, Volume: 13, Issue:13

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Carriers; Glioblastoma; Humans; Irinotecan; Metformin; Microscopy, Electron, Transmission; Nanoparticles; Neoplasms, Experimental; Neurons; Polylactic Acid-Polyglycolic Acid Copolymer; Rats

2018
Radiotherapy-Controllable Chemotherapy from Reactive Oxygen Species-Responsive Polymeric Nanoparticles for Effective Local Dual Modality Treatment of Malignant Tumors.
    Biomacromolecules, 2018, 09-10, Volume: 19, Issue:9

    Topics: Adipates; Animals; Antineoplastic Agents; Cell Line, Tumor; Chemoradiotherapy; Drug Liberation; Irinotecan; Male; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms, Experimental; Polyethylene Glycols; Reactive Oxygen Species; Safrole; X-Rays

2018
Irinotecan-Induced Mucositis Is Associated with Goblet Cell Dysregulation and Neural Cell Damage in a Tumour Bearing DA Rat Model.
    Pathology oncology research : POR, 2020, Volume: 26, Issue:2

    Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Enteric Nervous System; Female; Goblet Cells; Intestinal Mucosa; Irinotecan; Mucositis; Neoplasms, Experimental; Neurons; Rats

2020
Click chemistry-mediated tumor-targeting of SN38-loaded nanoparticles using trastuzumab.
    Biochemical and biophysical research communications, 2019, 07-12, Volume: 515, Issue:1

    Topics: Animals; Cell Line, Tumor; Click Chemistry; Cyclooctanes; Drug Delivery Systems; Irinotecan; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms, Experimental; Protein Binding; Receptor, ErbB-2; Tissue Distribution; Topoisomerase I Inhibitors; Trastuzumab

2019
Anticancer activity of polymeric nanoparticles containing linoleic acid-SN38 (LA-SN38) conjugate in a murine model of colorectal cancer.
    Colloids and surfaces. B, Biointerfaces, 2019, Sep-01, Volume: 181

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Cell Survival; Colonic Neoplasms; Drug Screening Assays, Antitumor; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Linoleic Acid; Male; Mice; Nanoparticles; Neoplasms, Experimental; Optical Imaging; Particle Size; Polymers; Rats; Rats, Sprague-Dawley; Surface Properties; Tissue Distribution; Tumor Cells, Cultured

2019
A predictive pharmacokinetic-pharmacodynamic model of tumor growth kinetics in xenograft mice after administration of anticancer agents given in combination.
    Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:2

    Topics: Algorithms; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Cell Line, Tumor; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kinetics; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Neoplasm Transplantation; Neoplasms, Experimental; Xenograft Model Antitumor Assays

2013
Identification of preferred chemotherapeutics for combining with a CHK1 inhibitor.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:11

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbolines; Cell Cycle Checkpoints; Checkpoint Kinase 1; Dacarbazine; Deoxycytidine; DNA Damage; Gemcitabine; HCT116 Cells; High-Throughput Nucleotide Sequencing; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms; Neoplasms, Experimental; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Temozolomide; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2013
Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Apr-15, Volume: 20, Issue:8

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Folic Acid; HeLa Cells; Humans; Irinotecan; Mice, Inbred BALB C; Mice, Inbred DBA; Mice, Nude; Neoplasms; Neoplasms, Experimental; Paclitaxel; Taxoids; Topotecan; Treatment Outcome; Vinca Alkaloids; Xenograft Model Antitumor Assays

2014
An activatable theranostic for targeted cancer therapy and imaging.
    Angewandte Chemie (International ed. in English), 2014, Apr-22, Volume: 53, Issue:17

    Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Survival; Diagnostic Imaging; Drug Delivery Systems; Fluorescent Dyes; Humans; Irinotecan; Mice; Molecular Imaging; Neoplasms, Experimental; Prodrugs; Sulfhydryl Compounds; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2014
Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-κB in vitro and in vivo.
    International journal of oncology, 2014, Volume: 45, Issue:3

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Movement; Colorectal Neoplasms; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Irinotecan; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; NF-kappaB-Inducing Kinase; Oligopeptides; Protein Serine-Threonine Kinases; Signal Transduction; Xenograft Model Antitumor Assays

2014
Tumor regression achieved by encapsulating a moderately soluble drug into a polymeric thermogel.
    Scientific reports, 2014, Jul-01, Volume: 4

    Topics: Animals; Camptothecin; Cell Line, Tumor; Diffusion; Hydrogels; Irinotecan; Mice; Mice, Nude; Nanocapsules; Neoplasms, Experimental; Particle Size; Polyesters; Polyethylene Glycols; Rabbits; Remission Induction; Solubility; Treatment Outcome

2014
Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models.
    Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:6

    Topics: Animals; Antineoplastic Agents; Camptothecin; Dogs; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Irinotecan; Male; Mice; Mice, Nude; Mice, SCID; Neoplasms, Experimental; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Species Specificity; Topoisomerase I Inhibitors; Treatment Outcome; Xenograft Model Antitumor Assays

2014
An activatable prodrug for the treatment of metastatic tumors.
    Journal of the American Chemical Society, 2014, Oct-01, Volume: 136, Issue:39

    Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; HeLa Cells; Humans; Hydrogen Peroxide; Irinotecan; Lung Neoplasms; Mice; Molecular Structure; Neoplasms, Experimental; Prodrugs; Structure-Activity Relationship; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2014
MBL-II-141, a chromone derivative, enhances irinotecan (CPT-11) anticancer efficiency in ABCG2-positive xenografts.
    Oncotarget, 2014, Dec-15, Volume: 5, Issue:23

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Chromatography, High Pressure Liquid; Chromones; HEK293 Cells; Humans; Indoles; Irinotecan; Mass Spectrometry; Mice; Neoplasm Proteins; Neoplasms, Experimental; Transfection; Xenograft Model Antitumor Assays

2014
Engineering of a lipid-polymer nanoarchitectural platform for highly effective combination therapy of doxorubicin and irinotecan.
    Chemical communications (Cambridge, England), 2015, Apr-04, Volume: 51, Issue:26

    Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line; Cell Proliferation; Doxorubicin; Drug Combinations; HeLa Cells; Humans; Irinotecan; Lecithins; Lipid Bilayers; MCF-7 Cells; Mice; Mice, Nude; Nanoparticles; Neoplasms, Experimental; Polymers; Structure-Activity Relationship

2015
Development of an oral nanotherapeutics using redox nanoparticles for treatment of colitis-associated colon cancer.
    Biomaterials, 2015, Volume: 55

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Azoxymethane; Camptothecin; Cell Line, Tumor; Colitis; Colonic Neoplasms; Dextrans; Drug Delivery Systems; Drug Screening Assays, Antitumor; Endoscopy; Free Radical Scavengers; Inflammation; Irinotecan; Male; Mice; Mice, Inbred ICR; Nanomedicine; Nanoparticles; Neoplasms, Experimental; Nitrogen Oxides; Oxidation-Reduction; Reactive Oxygen Species; Sulfates

2015
SN-38-loaded nanofiber matrices for local control of pediatric solid tumors after subtotal resection surgery.
    Biomaterials, 2016, Volume: 79

    Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Child, Preschool; Diffusion; Female; Humans; Irinotecan; Male; Mice; Nanocapsules; Nanofibers; Neoplasm Recurrence, Local; Neoplasms, Experimental; Particle Size; Postoperative Care; Tissue Distribution; Treatment Outcome

2016
Hypoxia-directed and activated theranostic agent: Imaging and treatment of solid tumor.
    Biomaterials, 2016, Volume: 104

    Topics: A549 Cells; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Proliferation; Fluorescent Dyes; HeLa Cells; Humans; Irinotecan; Neoplasms, Experimental; Oxygen; Theranostic Nanomedicine; Treatment Outcome; Tumor Hypoxia

2016
Irinotecan-loaded double-reversible thermogel with improved antitumor efficacy without initial burst effect and toxicity for intramuscular administration.
    Acta biomaterialia, 2017, Volume: 54

    Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Hydrogels; Injections, Intramuscular; Irinotecan; Lipids; Mice; Mice, Nude; Nanoparticles; Neoplasms, Experimental

2017
Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Nov-15, Volume: 14, Issue:22

    Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Hypoxia; Doxorubicin; Fluorouracil; Humans; Image Processing, Computer-Assisted; Immunohistochemistry; Irinotecan; Liposomes; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Mice; Nanocapsules; Neoplasms, Experimental; Neovascularization, Pathologic; Tissue Distribution; Xenograft Model Antitumor Assays

2008
Moxifloxacin increases anti-tumor and anti-angiogenic activity of irinotecan in human xenograft tumors.
    Biochemical pharmacology, 2010, Apr-15, Volume: 79, Issue:8

    Topics: Angiogenesis Inhibitors; Animals; Anti-Infective Agents; Antineoplastic Agents; Aza Compounds; Camptothecin; Cell Proliferation; Drug Synergism; Female; Fluoroquinolones; Humans; Interleukin-8; Irinotecan; Mice; Mice, SCID; Moxifloxacin; Neoplasms, Experimental; Platelet Endothelial Cell Adhesion Molecule-1; Quinolines; Ultrasonography, Doppler; Xenograft Model Antitumor Assays

2010
Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Oct-01, Volume: 16, Issue:19

    Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Female; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms, Experimental; Neovascularization, Pathologic; Neuroblastoma; Polyethylene Glycols; Survival Rate; Topoisomerase I Inhibitors

2010
New concept of cytotoxic immunoconjugate therapy targeting cancer-induced fibrin clots.
    Cancer science, 2011, Volume: 102, Issue:7

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Drug Design; Female; Fibrin; Immunotoxins; Irinotecan; Mice; Neoplasms, Experimental

2011
Augmented therapeutic efficacy of irinotecan is associated with enhanced drug accumulation.
    Cancer letters, 2011, Dec-08, Volume: 311, Issue:2

    Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Chromatography, High Pressure Liquid; Cysteine; Drug Synergism; Female; Humans; Immunohistochemistry; Irinotecan; Mice; Mice, Nude; Neoplasms, Experimental; Organoselenium Compounds; Selenocysteine; Xenograft Model Antitumor Assays

2011
Antitumor activity of IHL-305, a novel pegylated liposome containing irinotecan, in human xenograft models.
    Oncology reports, 2012, Volume: 27, Issue:1

    Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Humans; Irinotecan; Liposomes; Male; Mice; Mice, Nude; Neoplasms, Experimental; Polyethylene Glycols; Xenograft Model Antitumor Assays

2012
SN-38 loaded polymeric micelles to enhance cancer therapy.
    Nanotechnology, 2012, May-25, Volume: 23, Issue:20

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Survival; Diffusion; Humans; Irinotecan; Micelles; Nanocapsules; Neoplasms, Experimental; Tumor Cells, Cultured

2012
The role of natural killer cells in combinatorial anti-cancer therapy using Sindbis viral vectors and irinotecan.
    Cancer gene therapy, 2012, Volume: 19, Issue:8

    Topics: Animals; Camptothecin; Female; Humans; Irinotecan; Killer Cells, Natural; Mice; Mice, SCID; Neoplasms, Experimental; Oncolytic Virotherapy; Oncolytic Viruses; Ovarian Neoplasms; Sindbis Virus; Topoisomerase Inhibitors

2012
Alpha-tocopheryl polyethylene glycol succinate-emulsified poly(lactic-co-glycolic acid) nanoparticles for reversal of multidrug resistance in vitro.
    Nanotechnology, 2012, Dec-14, Volume: 23, Issue:49

    Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Emulsions; Humans; Irinotecan; Lactic Acid; Materials Testing; Nanocapsules; Nanoparticles; Neoplasms, Experimental; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Vitamin E

2012
KML001 displays vascular disrupting properties and irinotecan combined antitumor activities in a murine tumor model.
    PloS one, 2013, Volume: 8, Issue:1

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenites; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; Drug Synergism; Human Umbilical Vein Endothelial Cells; Humans; Irinotecan; Mice; Neoplasms, Experimental; Neovascularization, Pathologic; Sodium Compounds; Telomere

2013
Combined colonic cancer treatment with vitamin D analogs and irinotecan or oxaliplatin.
    Anticancer research, 2013, Volume: 33, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Dihydroxycholecalciferols; Female; HT29 Cells; Humans; Irinotecan; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Organoplatinum Compounds; Oxaliplatin; Signal Transduction; Vitamin D; Xenograft Model Antitumor Assays

2013
Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells.
    International journal of oncology, 2002, Volume: 21, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Division; Cell Survival; Colonic Neoplasms; DNA, Neoplasm; Drug Interactions; Female; Fluorouracil; Glutamates; Guanine; HT29 Cells; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms, Experimental; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Transplantation, Heterologous

2002
Small-sample inference for incomplete longitudinal data with truncation and censoring in tumor xenograft models.
    Biometrics, 2002, Volume: 58, Issue:3

    Topics: Algorithms; Animals; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Biometry; Camptothecin; Dacarbazine; Humans; Irinotecan; Longitudinal Studies; Mice; Neoplasm Transplantation; Neoplasms, Experimental; Temozolomide; Xenograft Model Antitumor Assays

2002
Experimental design and sample size determination for testing synergism in drug combination studies based on uniform measures.
    Statistics in medicine, 2003, Jul-15, Volume: 22, Issue:13

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Drug Synergism; Irinotecan; Mice; Models, Biological; Models, Statistical; Neoplasms, Experimental; Research Design; Sample Size; Statistics, Nonparametric; Temozolomide

2003
Development and characterization of a novel liposome-based formulation of SN-38.
    International journal of pharmaceutics, 2004, Feb-11, Volume: 270, Issue:1-2

    Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Chromatography, High Pressure Liquid; Drug Stability; Female; Hydrogen-Ion Concentration; Injections, Intravenous; Irinotecan; Liposomes; Male; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Neoplasms, Experimental; Time Factors; Transplantation, Heterologous

2004
Biological characterization of MLN944: a potent DNA binding agent.
    Molecular cancer therapeutics, 2004, Volume: 3, Issue:1

    Topics: Animals; Antigens, Neoplasm; Camptothecin; Catalysis; Cell Cycle; Cell Line, Tumor; Cluster Analysis; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; G1 Phase; G2 Phase; Gene Expression Profiling; HCT116 Cells; Humans; Intercalating Agents; Irinotecan; Male; Mice; Mice, Nude; Mitosis; Mutation; Neoplasms, Experimental; Phenazines; Transplantation, Heterologous; Xenograft Model Antitumor Assays; Yeasts

2004
Repeated-measures models with constrained parameters for incomplete data in tumour xenograft experiments.
    Statistics in medicine, 2005, Jan-15, Volume: 24, Issue:1

    Topics: Algorithms; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Female; Humans; Irinotecan; Likelihood Functions; Longitudinal Studies; Mice; Mice, SCID; Models, Biological; Models, Statistical; Neoplasms, Experimental; Rhabdomyosarcoma; Temozolomide; Xenograft Model Antitumor Assays

2005
Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy.
    The Journal of clinical investigation, 2005, Volume: 115, Issue:6

    Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms, Experimental; Oligonucleotide Array Sequence Analysis; Osteonectin; Transplantation, Heterologous

2005
Chemotherapy under cachectic conditions and the possibility of cachexia-controlled chemotherapy.
    Oncology reports, 2005, Volume: 14, Issue:1

    Topics: Animals; Antibodies; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cachexia; Camptothecin; Cell Line, Tumor; Cyclophosphamide; Dose-Response Relationship, Drug; Interleukin-6; Irinotecan; Male; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms, Experimental; Survival Analysis; Time Factors; Treatment Outcome

2005
Antivascular therapy of oral tongue squamous cell carcinoma with PTK787.
    The Laryngoscope, 2005, Volume: 115, Issue:12

    Topics: Animals; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Therapy, Combination; Follow-Up Studies; In Vitro Techniques; Irinotecan; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Phthalazines; Prodrugs; Protein Kinase Inhibitors; Pyridines; Tongue Neoplasms; Treatment Outcome

2005
Intraperitoneal versus intravenous CPT-11 given intra- and postoperatively for peritoneal carcinomatosis in a rat model.
    Surgery today, 2006, Volume: 36, Issue:1

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Enzyme Inhibitors; Infusions, Parenteral; Irinotecan; Male; Models, Animal; Neoplasm Transplantation; Neoplasms, Experimental; Peritoneal Neoplasms; Postoperative Period; Rats

2006
Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels.
    Molecular cancer therapeutics, 2006, Volume: 5, Issue:1

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cetuximab; Cisplatin; ErbB Receptors; Female; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms, Experimental; Xenograft Model Antitumor Assays

2006
Circadian regulation of mouse topoisomerase I gene expression by glucocorticoid hormones.
    Biochemical pharmacology, 2006, Apr-14, Volume: 71, Issue:8

    Topics: Adrenalectomy; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Circadian Rhythm; DNA Topoisomerases, Type I; Gene Expression Regulation, Neoplastic; Glucocorticoids; Irinotecan; Male; Mice; Mice, Inbred ICR; Neoplasm Transplantation; Neoplasms, Experimental; Receptors, Glucocorticoid; Topoisomerase I Inhibitors

2006
Effect of a novel vacuolar-H+-ATPase inhibitor on cell and tumor response to camptothecins.
    The Journal of pharmacology and experimental therapeutics, 2006, Volume: 318, Issue:3

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Camptothecin; Enzyme Inhibitors; Female; HT29 Cells; Humans; Indoles; Irinotecan; Mice; Neoplasm Proteins; Neoplasms, Experimental; Staining and Labeling; Topotecan; Vacuolar Proton-Translocating ATPases

2006
Preclinical efficacy of ST1976, a novel camptothecin analog of the 7-oxyiminomethyl series.
    Biochemical pharmacology, 2007, Mar-01, Volume: 73, Issue:5

    Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; DNA Cleavage; DNA Topoisomerases, Type I; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Mice; Mice, Nude; Molecular Structure; Neoplasms, Experimental

2007
MEK activation suppresses CPT11-induced apoptosis in rat intestinal epithelial cells through a COX-2-dependent mechanism.
    Digestive diseases and sciences, 2007, Volume: 52, Issue:10

    Topics: Animals; Apoptosis; Blotting, Western; Camptothecin; Cell Survival; Cyclooxygenase 2; Enzyme Activation; Enzyme Inhibitors; Epithelial Cells; Intestinal Mucosa; Intestinal Neoplasms; Irinotecan; Mitogen-Activated Protein Kinase Kinases; Neoplasms, Experimental; Rats; Signal Transduction; Tumor Cells, Cultured

2007
Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Feb-15, Volume: 14, Issue:4

    Topics: Animals; Antineoplastic Agents; Camptothecin; Female; Humans; Irinotecan; Liposomes; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Xenograft Model Antitumor Assays

2008
Bolus oral glutamine protects rats against CPT-11-induced diarrhea and differentially activates cytoprotective mechanisms in host intestine but not tumor.
    The Journal of nutrition, 2008, Volume: 138, Issue:4

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Camptothecin; Colon; Colonic Neoplasms; Cytoprotection; Diarrhea; Female; Glutamine; Irinotecan; Neoplasms, Experimental; Rats

2008
DTS-108, a novel peptidic prodrug of SN38: in vivo efficacy and toxicokinetic studies.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Apr-01, Volume: 14, Issue:7

    Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cations; Dogs; Drug Carriers; Humans; Irinotecan; Neoplasms, Experimental; Peptides; Prodrugs; Xenograft Model Antitumor Assays

2008
Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
    Cancer chemotherapy and pharmacology, 1995, Volume: 36, Issue:5

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Colonic Neoplasms; Female; Humans; Irinotecan; Mice; Mice, Inbred CBA; Neoplasms, Experimental; Random Allocation; Rhabdomyosarcoma; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured

1995
CPT-11: a novel antitumor drug.
    Japanese journal of cancer research : Gann, 1994, Volume: 85, Issue:8

    Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Survival; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Irinotecan; Mice; Mice, Inbred C3H; Molecular Structure; Neoplasms, Experimental; Topoisomerase I Inhibitors; Tumor Cells, Cultured

1994
Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.
    Anti-cancer drugs, 1996, Volume: 7, Issue:4

    Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Docetaxel; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Irinotecan; Leukemia, Experimental; Male; Mice; Mice, Inbred Strains; Neoplasms, Experimental; Paclitaxel; Sensitivity and Specificity; Taxoids; Vincristine

1996
Schedule-dependent efficacy of camptothecins in models of human cancer.
    Annals of the New York Academy of Sciences, 1996, Dec-13, Volume: 803

    Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Irinotecan; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Neoplasms, Experimental; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured

1996
Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo.
    International journal of cancer, 1997, Nov-27, Volume: 73, Issue:5

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Death; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Fluorouracil; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Survival Analysis; Topoisomerase I Inhibitors

1997
Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II.
    Japanese journal of cancer research : Gann, 1997, Volume: 88, Issue:10

    Topics: Adenocarcinoma; Aminoquinolines; Animals; Antineoplastic Agents; Camptothecin; Cisplatin; Colonic Neoplasms; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Etoposide; Humans; Indenes; Indoles; Irinotecan; Lung Neoplasms; Male; Melanoma; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Neoplasms, Experimental; Pyridines; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured

1997
Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB.
    Nature medicine, 1999, Volume: 5, Issue:4

    Topics: Adenoviridae; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; DNA-Binding Proteins; Drug Resistance; Female; Genetic Therapy; I-kappa B Proteins; Irinotecan; Mice; Mice, Nude; Neoplasms, Experimental; NF-kappa B; NF-KappaB Inhibitor alpha; Recombinant Proteins; Tumor Necrosis Factor-alpha

1999
Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:4

    Topics: Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Catalysis; Cell Division; Drug Screening Assays, Antitumor; Humans; Irinotecan; Mice; Mice, Inbred CBA; Molecular Sequence Data; Neoplasm Transplantation; Neoplasms, Experimental; Nitrobenzenes; Phenylacetates; Prodrugs; Rabbits; Tumor Cells, Cultured

1999
Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor.
    Cancer research, 2001, Jan-15, Volume: 61, Issue:2

    Topics: Animals; Antineoplastic Agents; Apoptosis; Bacterial Infections; Camptothecin; Cell Line; Cell Survival; Female; Fluorouracil; Glucagon-Like Peptide 2; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Intestines; Irinotecan; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms; Neoplasms, Experimental; Peptides; Rats; Receptors, Glucagon; Survival Rate; Time Factors; Transfection; Tumor Cells, Cultured

2001
GEM 231, a second-generation antisense agent complementary to protein kinase A RIalpha subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts.
    International journal of oncology, 2002, Volume: 21, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Camptothecin; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Oligonucleotides; Oligonucleotides, Antisense; Pancreatic Neoplasms; Prostatic Neoplasms; Survival Rate; Treatment Outcome

2002
Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, phar
    International journal of oncology, 2002, Volume: 21, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Oligonucleotides; Oligonucleotides, Antisense; Prostatic Neoplasms; Survival Rate; Tissue Distribution; Treatment Outcome

2002
Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice.
    International journal of cancer, 1992, Mar-12, Volume: 50, Issue:5

    Topics: Animals; Antineoplastic Agents; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Doxorubicin; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Topoisomerase II Inhibitors; Transplantation, Heterologous

1992
[Effect of administration schedules on the antitumor activity of CPT-11, a camptothecin derivative].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1990, Volume: 17, Issue:1

    Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Fibrosarcoma; Injections, Intraperitoneal; Injections, Intravenous; Irinotecan; Leukemia L1210; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms, Experimental

1990
Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo.
    Cancer chemotherapy and pharmacology, 1988, Volume: 21, Issue:1

    Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Doxorubicin; Drug Resistance; Irinotecan; Leukemia P388; Neoplasms, Experimental; Tumor Cells, Cultured; Vincristine

1988
[Antitumor activity of new derivatives of camptothecin].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1987, Volume: 14, Issue:3 Pt 2

    Topics: Animals; Antineoplastic Agents; Camptothecin; Doxorubicin; Irinotecan; Lethal Dose 50; Leukemia L1210; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred ICR; Neoplasms, Experimental

1987
Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors.
    Cancer research, 1987, Nov-15, Volume: 47, Issue:22

    Topics: Animals; Antineoplastic Agents; Camptothecin; Dose-Response Relationship, Drug; Irinotecan; Mice; Mice, Inbred Strains; Neoplasms, Experimental

1987